First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA
Preclinical presentation to feature ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer, exploring its potential across molecular subtypes
ATNM-400's HER3-targeted alpha radiotherapy approach offers pan-cancer potential, with development as a monotherapy and in combination with established treatments across multiple solid tumors.

 

EANM 2026 Presentation Details

Both sessions: Monday, October 19, 2026, 4:45–6:15 p.m. CEST (10:45 a.m.–12:15 p.m. EDT).

Clinical prostate cancer presentation | OP-525

First-in-human Phase 1 study of ATNM-400 in mCRPC

Session 1111: Theranostics Track: Prostate Cancer Therapy II | Hall G1

Preclinical lung cancer presentation | EPS-149

ATNM-400 in KRAS- and ALK-driven NSCLC models

Session 1109: Translational Imaging and Therapy | Hall G2

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.